Back to trial detailsIntake questionnaire
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Applying to HonorHealth Research Institute · Scottsdale, Arizona
Answer a few short questions to share with the research team.
0 of 3 answered